Takayasu's arteritis medical therapy
Jump to navigation
Jump to search
|
Takayasu's arteritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Takayasu's arteritis medical therapy On the Web |
|
American Roentgen Ray Society Images of Takayasu's arteritis medical therapy |
|
Risk calculators and risk factors for Takayasu's arteritis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
Pharmacologic medical therapy is recommended among patients with Takayasu’s arteritis to control inflammatory process and hypertension. Pharmacologic medical therapies for include corticosteroids, IL-6 receptor inhibitor, B-cell depletion agents, and cytotoxic drugs.
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with Takayasu’s arteritis to control inflammatory process and hypertension.[1][2]
- Pharmacologic medical therapies for include corticosteroids, IL-6 receptor inhibitor, B-cell depletion agents, and cytotoxic drugs.
Takayasu’s arteritis
- 1 Corticosteroids
- Preferred regimen (1): prednisone 1 mg/kg PO qd (Consider osteoporosis prevention)
- 2 IL-6 receptor inhibitor
- Preferred regimen (1): Tocilizumab
- 3 B-cell depletion
- Preferred regimen (1): Rituximab
- 4 Cytotoxic agents
- Preferred regimen (1): methotrexate
- Preferred regimen (2): azathioprine
- Preferred regimen (3): cyclophosphamide
References
- ↑ Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE (January 1977). "Takayasu's arteritis. Clinical study of 107 cases". Am. Heart J. 93 (1): 94–103. PMID 12655.
- ↑ Keser G, Direskeneli H, Aksu K (May 2014). "Management of Takayasu arteritis: a systematic review". Rheumatology (Oxford). 53 (5): 793–801. doi:10.1093/rheumatology/ket320. PMID 24097290.